BANGKOK GENOMICS INNOVATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.92 THB | -2.01% |
|
-2.67% | -.--% |
Valuation
| Fiscal Period: December | 2024 |
|---|---|
| Capitalization 1 | 1,752 |
| Enterprise Value (EV) 1 | 1,752 |
| P/E ratio | - |
| Yield | 1.37% |
| Capitalization / Revenue | - |
| EV / Revenue | - |
| EV / EBITDA | - |
| EV / FCF | - |
| FCF Yield | - |
| Price to Book | 2.35 x |
| Nbr of stocks (in thousands) | 600,000 |
| Reference price 2 | 2.920 |
| Announcement Date | - |
1THB in Million2THB
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 32.14 | - |
| Net margin | - | - |
| EPS | 0.0700 | - |
| Free Cash Flow | - | - |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share 1 | - | 0.0400 |
| Announcement Date | 3/19/24 | - |
1THB
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net Debt | - | - |
| Net Cash position | - | - |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | - |
| ROE (net income / shareholders' equity) | - | - |
| ROA (Net income/ Total Assets) | - | - |
| Assets | - | - |
| Book Value Per Share 1 | - | 1.240 |
| Cash Flow per Share | - | - |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 3/19/24 | - |
1THB
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 47.58M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- BKGI Stock
- Financials Bangkok Genomics Innovation
